18
Participants
Start Date
September 30, 2013
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
AXIS Clinical Trials Research Center, Los Angeles
Collaborators (1)
Triligent International
INDUSTRY
Analytical Bio-Chemistry Laboratories, Inc.
INDUSTRY
Rho, Inc.
INDUSTRY
St. Renatus, LLC
INDUSTRY